Announcements Trials
Browse Landscape

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Vascular Diseases 2Heart Diseases 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Second Primary 1Metabolic Diseases 1Heart Failure 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Cancer Metastatic 1Cardiovascular Diseases 1Cardiotoxicity 1Cancer Therapy-related Cardiovascular Toxicity 1Breast Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Gonadotropin-Releasing Hormone 2xinmailong 1palbociclib 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Vitamin B 6 1Vitamin B 12 1Testosterone 1Rivaroxaban 1Progesterone 1Genetic Testing 1Folic Acid 1Estradiol 1DNA 1Cardiovascular Agents 1Blood Specimen Collection 1Antineoplastic Agents 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Cardiovascular Diseases × Antineoplastic Agents × Clear all
NCT06409481 2024-05-10

PARCA

The First Affiliated Hospital of Xinxiang Medical College

Unknown
800,000 enrolled

Cardiovascular Diseases, Heart Diseases, Neoplasms, Vascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡